BRAINSTORM CELL THERAPEUTICS INC.
BRAINSTORM CELL THERAPEUTICS INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 13, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.
Cash runway is approximately 0.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 5 concluded trials, 100% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 13, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 1, 2028 | Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY) | Trial Milestone | Phase 3 |
Track BCLI alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BCLI in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.